IMV バランスシートの健全性

財務の健全性基準チェック /06

IMVの健全性を判断するにはデータが不十分です

主要情報

n/a

負債資本比率

n/a

負債

インタレスト・カバレッジ・レシオ	n/a
現金	n/a
エクイティ	n/a
負債合計	n/a
総資産	n/a

財務の健全性に関する最新情報

Recent updates

IMV T cell therapy shows positive action in treatment-resistant ovarian cancer; shares up 5%

Dec 03

IMV reports Q3 results

Nov 12

財務状況分析

短期負債: IMVI.Fの短期資産が短期負債をカバーしているかどうかを判断するにはデータが不十分です。

長期負債: IMVI.Fの短期資産が長期負債をカバーしているかどうかを判断するにはデータが不十分です。

デット・ツー・エクイティの歴史と分析

負債レベル: IMVI.Fの純負債対資本比率を計算して満足できるものであるかどうかを判断するにはデータが不十分です。

負債の削減: IMVI.Fの負債対資本比率が過去 5 年間で減少したかどうかを判断するにはデータが不十分です。

債務返済能力: IMVI.Fの負債が営業キャッシュフローによって十分にカバーされているかどうかを判断するにはデータが不十分です。

インタレストカバレッジ: IMVI.Fの負債に対する利息支払いが EBIT によって十分にカバーされているかどうかを判断するにはデータが不十分です。

IMV バランスシートの健全性

財務の健全性 基準チェック /06

主要情報

財務の健全性に関する最新情報

IMV Inc. Files Form 15

Nasdaq to Delist the Common Shares of IMV

IMV Receives Nasdaq Delisting Notice

IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Recent updates

IMV Inc. Files Form 15

Nasdaq to Delist the Common Shares of IMV

IMV Inc.(OTCPK:IMVI.Q) dropped from NASDAQ Composite Index

IMV Receives Nasdaq Delisting Notice

IMV Inc. Presents Positive Initial Results from the MVP-S Phase 2B Vitalize Trial

High number of new directors

IMV Inc. Announces Board Changes

IMV Inc. has completed a Follow-on Equity Offering in the amount of $9 million.

IMV Inc. has completed a Follow-on Equity Offering in the amount of $9 million.

Imv Inc. Announces Initial Data from the Ongoing Phase 2B Vitalize Trial in Patients with R/R Dlbcl

IMV Inc. to Report Q3, 2022 Results on Nov 11, 2022

IMV Inc. Announces Board Changes

IMV to cut ~33% workforce amid reorganization

High number of new directors

IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

IMV receives Nasdaq non-compliance letter

High number of new directors

IMV Inc. Announces Andrew Sheldon Not Stand for Re-Election to the Board

IMV Inc. announced that it has received $25 million in funding from Horizon Technology Finance Management, LLC

IMV Inc. Appoints Michael P. Bailey as Chairman of the Board

IMV Inc., Annual General Meeting, Jun 14, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

IMV Announces First Patient Dosed in the VITALIZE Phase 2B Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA® (pembrolizumab) in Patients with r/r DLBCL

IMV Inc Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts

IMV Inc. announces new translational data implicating B cells in the clinical benefit induced by MVP-S treatment in ovarian cancer patients

IMV Inc. Announces First Patient Dosed in Phase 1b Clinical Study Evaluating its Lead Compound in Patients with Breast Cancer

IMV Inc. Announces Final Topline Results of the Decide1 Clinical Trial

CEO & Director Frederic Ors has left the company

High number of new directors

CEO & Director recently bought US$147k worth of stock

Chief Medical Officer Joanne Schindler has left the company

IMV names Jeremy Graff as chief scientific officer

Imv Inc. Leads Immunotherapy to Be Investigated in Breast Cancer

Independent Director has left the company

Full year 2020 earnings released: CA$0.58 loss per share (vs CA$0.55 loss in FY 2019)

IMV Inc. to Report Q4, 2020 Results on Mar 17, 2021

New 90-day high: US$4.36

IMV Reports Update on COVID-19 Vaccine Program

IMV's vaccine candidate potentially effective against COVID-19, shares up 16%

New 90-day low: US$3.13

Durable Clinical Benefits Induced by IMV’s T Cell Therapy in Combination With Merck’s Keytruda in Subjects With PD-L1 Positive r/r DLBCL Presented at ASH Annual Meeting

IMV’s Survivin-Targeted T Cell Therapy Shows Durable Clinical Benefits in Phase 2 Study in Patients with Hard-to-Treat Advanced Recurrent Ovarian Cancer

IMV T cell therapy shows positive action in treatment-resistant ovarian cancer; shares up 5%

Revenue and earnings beat expectations

IMV reports Q3 results

IMV Inc. Appoints Andrew Hall as Chief Business Officer

IMV's T Cell Therapy Demonstrates 86% Objective Response Rate in Combination with Merck's Keytruda® in PD-L1 Positive Patients with r/r DLBCL

IMV Inc. Provides Updated Clinical Data from Phase 2 SPiReL Study Evaluating its T Cell Therapy in Combination with Merck’s Keytruda in Patients with R/R DLBCL

New 90-day low: US$3.15

IMV Inc Announces That Biomarkers Associated with Clinical Response in Patients with R/R DLBCL Treated with DPX-Survivac

New 90-day low: US$3.85

IMV Inc. Provides Updates on Its Vaccine Candidate, DPX-COVID-19, for the Prevention of Infection Caused by the Novel Coronavirus SARS-COV-2

Earnings released

IMV Inc. to Report Q2, 2020 Results on Aug 12, 2020

財務状況分析

デット・ツー・エクイティの歴史と分析

貸借対照表

健全な企業の発掘

財務の健全性基準チェック /06